ArticleJournal of cellular and molecular medicine2012
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study.
Article in Journal of cellular and molecular medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.The oncologist · 2016Pooled it
- A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?Cancer biology & therapy · 2015Pooled it
- Advances in PD-1/PD-L1 pathway inhibitors in the treatment of thyroid cancer: mechanisms and clinical therapeutic perspectives.Frontiers in immunology · 2025Review
- Article
- Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines.Molecular oncology · 2017Article
- The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts.International journal of molecular sciences · 2016Article
- CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR.Oncotarget · 2016Article
- Article
- The cAMP analogs have potent anti-proliferative effects on medullary thyroid cancer cell lines.Endocrine · 2016Article
- Article
- New therapies for dedifferentiated papillary thyroid cancer.International journal of molecular sciences · 2015Review
- PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.Endocrine · 2015Review
- Article
- Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial.International journal of endocrinology · 2015Article
- Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells.Cancer biology & therapy · 2015Article
- Igf-I influences everolimus activity in medullary thyroid carcinoma.Frontiers in endocrinology · 2015Article
- Cabozantinib for progressive metastatic medullary thyroid cancer: a review.Therapeutics and clinical risk management · 2014Review
- Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells.Endocrine-related cancer · 2012Article
- Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy.Endocrine · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Everolimus, an mTOR inhibitor, which has been demonstrated to induce anti-tumour effects in different types of neuroendocrine tumours, has never been evaluated in patients with medullary thyroid cancer (MTC). The aim of this study was to evaluate the in vitro and in vivo effects of everolimus in combination with octreotide in MTC. Two patients with progressive metastatic MTC and high calcitonin levels were treated with everolimus 5-10 mg/day. Both patients were under treatment with octreotide LAR at the study entry. An in vitro study was also performed to assess everolimus effects on MTC cell lines (TT and MZ-CRC-1 cells). A tumour response was observed in both patients. Serum calcitonin decreased by 86% in patient 1 and by 42% in patient 2. In TT and MZ-CRC-1 cells, everolimus induced a significant dose-dependent inhibition in cell proliferation. This effect seems to be related to a cell cycle arrest in G(0) /G(1) phase in both cell lines and to the induction of cellular senescence in TT cells. Everolimus in combination with octreotide may be active as anti-tumour therapy in patients with progressive metastatic MTC, suggesting to further evaluate this agent in MTC patients in a large prospective study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.